Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$77.93 USD

77.93
3,220,670

-0.68 (-0.87%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $77.93 0.00 (0.00%) 7:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

OCPNY vs. EW: Which Stock Is the Better Value Option?

by Zacks Equity Research

OCPNY vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

Edwards Lifesciences (EW) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Edwards Lifesciences (EW) closed the most recent trading day at $90.79, moving +1.62% from the previous trading session.

Zacks Equity Research

Edwards Lifesciences (EW) Stock Moves -1.18%: What You Should Know

by Zacks Equity Research

In the latest trading session, Edwards Lifesciences (EW) closed at $87.73, marking a -1.18% move from the previous day.

Zacks Equity Research

Edwards Lifesciences (EW) Stock Moves -0.68%: What You Should Know

by Zacks Equity Research

Edwards Lifesciences (EW) closed at $93 in the latest trading session, marking a -0.68% move from the prior day.

Zacks Equity Research

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

OCPNY vs. EW: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

OCPNY vs. EW: Which Stock Is the Better Value Option?

Sheraz Mian headshot

Top Stock Reports for Eli Lilly, ConocoPhillips & PNC Financial

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), ConocoPhillips (COP), and The PNC Financial Services Group, Inc. (PNC).

Zacks Equity Research

Why Is Edwards Lifesciences (EW) Down 11.8% Since Last Earnings Report?

by Zacks Equity Research

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

The Zacks Analyst Blog Highlights Comcast, CME Group, Charter Communications, Airbnb, and Edwards Lifesciences

by Zacks Equity Research

Comcast, CME Group, Charter Communications, Airbnb, and Edwards Lifesciences are part of Top analyst Blog.

Mark Vickery headshot

Top Analyst Reports for Comcast, CME & Charter Communications

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Comcast Corporation (CMCSA), CME Group Inc. (CME), and Charter Communications, Inc. (CHTR).

Zacks Equity Research

Here's Why You Should Hold on to Edwards Lifesciences (EW) Now

by Zacks Equity Research

Investors are optimistic about Edwards Lifesciences (EW) given the strong demand for its RESILIA tissue valves and the PASCAL system.

Zacks Equity Research

The Zacks Analyst Blog Highlights T-Mobile US, Deere, PayPal, The PNC Financial Services Group and Edwards Lifesciences

by Zacks Equity Research

T-Mobile US, Deere, PayPal, The PNC Financial Services Group and Edwards Lifesciences have been included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for T-Mobile, Deere & PayPal

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Deere & Company (DE), and PayPal Holdings, Inc. (PYPL).

Zacks Equity Research

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

IART vs. EW: Which Stock Is the Better Value Option?

by Zacks Equity Research

IART vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

Edwards Lifesciences (EW) Q1 Earnings Top Estimates, Margins Up

by Zacks Equity Research

Increased adoption of the PASCAL platform along with continued strength in the HemoSphere monitoring platform drove Edwards Lifesciences' (EW) Q1 revenues.

Zacks Equity Research

Edwards Lifesciences (EW) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 3.45% and 2.44%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Humana (HUM) Gears Up For Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Humana's (HUM) first-quarter earnings are likely to reflect the impacts of elevated costs related to investments in technology advancements, partly offset by higher premiums in the Retail segment and sound membership growth.

Zacks Equity Research

Edwards Lifesciences (EW) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Improvement in TAVR and TMTT businesses is expected to have contributed to Edwards Lifesciences' (EW) first-quarter performance.

Zacks Equity Research

Edwards Lifesciences (EW) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Edwards Lifesciences (EW) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Edwards Lifesciences (EW) closed at $121.91 in the latest trading session, marking a +0.89% move from the prior day.

Zacks Equity Research

Abiomed (ABMD) Announces Successful Usage of Impella in Japan

by Zacks Equity Research

Continued adoption of Abiomed's (ABMD) Impella 5.5 with SmartAssist is likely to provide a minimally invasive surgical option for acute heart failure patients.

Zacks Equity Research

Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.

Zacks Equity Research

AmerisourceBergen's (ABC) Venture Capital Fund to Aid Healthcare

by Zacks Equity Research

AmerisourceBergen's (ABC) new corporate venture capital fund to help emerging healthcare startup companies change healthcare for people and animals globally.

Zacks Equity Research

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.